The Motley Fool Discussion Boards

Previous Page

Social Clubs / The World is Flat


Subject:  Re: NASH thoughts Date:  6/18/2019  8:58 AM
Author:  2K10 Number:  235 of 252

Fuma -- thanks for your background thoughts on NASH.

I am in a Canadian company Theratechnologies (OTC: THERF) which is already treating HIV patients with fatty liver with EGRIFTA containing Tesamorelin so should have a decent safety profile.

This week they announced good results in trying to extend the label on Tesamorelin to NASH.

The stock is down since the announcement so maybe the market sees similar business case as you do.

However Tesamorelin is not why I'm in THERF, I am hoping for commercial success of their HIV drug

I don't have the deep background into pharma companies that you do. Have you ever looked at Theratechnologies?
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us